It's Time to Face the Zerit Problem (March 2003)
Nelson Vergel urges Bristol-Myers Squibb to do more to minimize the lipoatrophy effects of d4T (stavudine, Zerit), and recommends it no longer be used as first-line treatment in the meantime.
In GMHC Treatment Issues, from Gay Men's Health Crisis
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.